Hall Render

FEBRUARY 18, 2022

Meet new FDA chief Dr. Robert Califf: 5 things to know. Outpatient push being felt in architecture industry. Florida physician convicted of $110M fraud. Bill on prescription drug pricing inspires support from Maine residents, opposition from pharmaceutical industry. billing fraud. 7 ASC moves in Florida.

COVID-19 40

COVID-19 Nursing Homes Nurses COVID-19 Vaccine 40

Hall Render

APRIL 21, 2023

health care fraud scheme SA cancer research company entering Dallas market as it eyes more U.S., health care fraud scheme SA cancer research company entering Dallas market as it eyes more U.S., European expansion North Texas podiatrist and patient recruiter convicted in $8.5M

US Department of Health and Human Services 40

US Department of Health and Human Services COVID-19 Nurses Nursing Homes 40

Kaiser Health News

NOVEMBER 1, 2024

Letting them expire “would reduce fraud and waste ,” said Brian Blase, a former Trump adviser who is president of the Paragon Health Institute, a conservative policy research firm. For instance, the FDA could reduce availability of the abortion pill mifepristone or cancel its approval.

ACA 117

ACA FDA Medicaid Medicaid 117

Drug & Device Law

FEBRUARY 11, 2024

FDA litigation that is now before the Supreme Court. FDA , 78 F.4th quoting FDA appellate brief ). Congress created an FDA approval process that is both rigorous and thorough, and pharmaceutical companies invest billions of dollars in research and development to meet FDA’s scientific standards.

FDA 59

FDA Fraud Pharmaceutical Industry Doctors 59

Drug & Device Law

NOVEMBER 4, 2023

Learn an important preemption decision for our FDA-regulated sandbox that did not involve any of these products (and now has dodged a potential Supreme Court bullet). Related consumer fraud/economic loss claims also regularly abound.

FDA 59

FDA Pharmaceutical Industry Licensing Fraud 59

Drug & Device Law

MARCH 7, 2022

Here, Plaintiffs fail to supply factual support showing Defendant acted with “oppression, fraud, or malice,” relying instead upon conclusory allegations. These allegations lack any contention or inference that [defendant] withheld or misrepresented information to the FDA. . ., at *8 (agreeing with Bouncing Angels, Inc. 2, 2020). “In

Fraud 59

Fraud FDA Licensing Pharmaceutical Industry 59